1
|
Dragoș ML, Ivanov IC, Mențel M, Văcărean-Trandafir IC, Sireteanu A, Titianu AA, Dăscălescu AS, Stache AB, Jitaru D, Gorgan DL. Prognostic Value of Association of Copy Number Alterations and Cell-Surface Expression Markers in Newly Diagnosed Multiple Myeloma Patients. Int J Mol Sci 2022; 23:ijms23147530. [PMID: 35886877 PMCID: PMC9318311 DOI: 10.3390/ijms23147530] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2022] [Revised: 06/29/2022] [Accepted: 07/05/2022] [Indexed: 11/16/2022] Open
Abstract
Multiple myeloma results from the clonal proliferation of abnormal plasma cells (PCs) in the bone marrow (BM). In this study, the cell surface expression markers (CD) on atypical PCs (detected by multiparametric flow cytometry (MFC)) were correlated with copy number alterations (CNAs) in the genome (detected by multiplex ligation-dependent probe amplification (MLPA)) to assess their impact on prognosis in newly diagnosed MM patients. Statistically significant results were obtained when different stages of PC maturation (classified based on CD19 and CD81 expression) were associated with CD117 expression and identified CNAs. In the intermediately differentiated PC group (CD19(−) CD81(+)), patients who didn’t express CD117 had a lower median progression free survival (PFS) (p = 0.024). Moreover, within this group, patients with less than three adverse CNAs, which harbor CD117, had a better outcome with a PFS of more than 48 months compared with 19 months (p = 0.008). Considering all the results, our study suggested the need to integrate both the CD markers and copy number alterations to evaluate the prognosis of newly diagnosed multiple myeloma patients.
Collapse
Affiliation(s)
- Mihaiela L. Dragoș
- Biology Department, Faculty of Biology, “Alexandru Ioan Cuza” University of Iasi, 700506 Iasi, Romania; (M.L.D.); (A.B.S.)
| | - Iuliu C. Ivanov
- Molecular Diagnosis Department, Regional Institute of Oncology, 700483 Iasi, Romania; (I.C.I.); (A.S.)
| | - Mihaela Mențel
- Center for Fundamental Research and Experimental Development in Translation Medicine—TRANSCEND, Regional Institute of Oncology, 700483 Iasi, Romania; (M.M.); (I.C.V.-T.)
- Immunophenotyping Department, Regional Institute of Oncology, 700483 Iasi, Romania
| | - Irina C. Văcărean-Trandafir
- Center for Fundamental Research and Experimental Development in Translation Medicine—TRANSCEND, Regional Institute of Oncology, 700483 Iasi, Romania; (M.M.); (I.C.V.-T.)
| | - Adriana Sireteanu
- Molecular Diagnosis Department, Regional Institute of Oncology, 700483 Iasi, Romania; (I.C.I.); (A.S.)
| | - Amalia A. Titianu
- Department of Hematology, Regional Institute of Oncology, 700483 Iasi, Romania; (A.A.T.); (A.S.D.)
- Department of Hematology, “Grigore T. Popa” University of Medicine and Pharmacy, 16 University Street, 700115 Iasi, Romania
| | - Angela S. Dăscălescu
- Department of Hematology, Regional Institute of Oncology, 700483 Iasi, Romania; (A.A.T.); (A.S.D.)
- Department of Hematology, “Grigore T. Popa” University of Medicine and Pharmacy, 16 University Street, 700115 Iasi, Romania
| | - Alexandru B. Stache
- Biology Department, Faculty of Biology, “Alexandru Ioan Cuza” University of Iasi, 700506 Iasi, Romania; (M.L.D.); (A.B.S.)
- Molecular Diagnosis Department, Regional Institute of Oncology, 700483 Iasi, Romania; (I.C.I.); (A.S.)
| | - Daniela Jitaru
- Biology Department, Faculty of Biology, “Alexandru Ioan Cuza” University of Iasi, 700506 Iasi, Romania; (M.L.D.); (A.B.S.)
- Correspondence: (D.J.); (D.L.G.); Tel.: +40-723-780-266 (D.J.); +40-0232-201-102 (ext. 1574) (D.L.G.)
| | - Dragoș L. Gorgan
- Biology Department, Faculty of Biology, “Alexandru Ioan Cuza” University of Iasi, 700506 Iasi, Romania; (M.L.D.); (A.B.S.)
- Correspondence: (D.J.); (D.L.G.); Tel.: +40-723-780-266 (D.J.); +40-0232-201-102 (ext. 1574) (D.L.G.)
| |
Collapse
|
2
|
Das N, Dahiya M, Gupta R, Rai S, Singh S, Prajapati VK, Kumar L, Sharma A, Sahoo RK, Gogia A. Flow cytometric immunophenotyping of plasma cells across the spectrum of plasma cell proliferative disorders: A fresh insight with pattern-based recognition. CYTOMETRY. PART B, CLINICAL CYTOMETRY 2022; 102:292-302. [PMID: 35212134 DOI: 10.1002/cyto.b.22062] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/07/2021] [Revised: 01/12/2022] [Accepted: 02/10/2022] [Indexed: 11/11/2022]
Abstract
BACKGROUND The expression pattern of common antigens including cytoplasmic kappa/lambda ratio (cyKLR) was evaluated by flow cytometric immunophenotyping (FCMI) to explore their relevance in discriminating normal and aberrant plasma cells (NPC and APC, respectively) across spectrum of plasma cell proliferative disorders (PCPD). METHODS In this prospective analysis, 791 samples from PCPD (treatment naive = 455; partially treated = 336) were evaluated for expression of CD38, CD138, CD45, CD19, CD56, CD27, CD81, CD117, Cy-kappa, and Cy-lambda using FCMI. RESULTS Amongst the entire cohort, 20.7% (n = 164) samples displayed only APC, 21% (n = 165) only NPC and 58% (n = 462) showed coexistence of NPC and APC. Using pattern-based recognition (PBR) for three common patterns (CD19 vs. CD56; CD27 vs. CD56 and CD19 vs. CD27), APC was separable from NPC in 93% samples. In 6.5% samples, the gating markers contributed in APC-NPC differentiation and in the remaining 0.5% CD117 and CD81 proved useful. Clonality assessment was found to be crucial to label plasma cell compartment as completely normal or aberrant in 42% cases with either all NPC or all APC. Sixty one out of 462 cases (13%) revealed cyKLR within normal reference range and in these cases; abnormal cyKLR was demonstrable only after gating APC separately based on PBR. CONCLUSION Fair discrimination between NPC and APC is achievable in all PCPD samples using eight markers (Gating: CD38, CD138, CD45; PBR:CD19, CD56, CD27; clonality: Cy-kappa and Cy-lambda). Thus, combined assessment of clonality and immunophenotypic aberrancies is required for accurate, reliable and precise assessment of NPC and APC compartments in PCPD.
Collapse
Affiliation(s)
- Nupur Das
- Department of Laboratory Oncology, Dr. B.R. Ambedkar IRCH, All India Institute of Medical Sciences (AIIMS), New Delhi, India
| | - Meetu Dahiya
- Department of Laboratory Oncology, Dr. B.R. Ambedkar IRCH, All India Institute of Medical Sciences (AIIMS), New Delhi, India
| | - Ritu Gupta
- Department of Laboratory Oncology, Dr. B.R. Ambedkar IRCH, All India Institute of Medical Sciences (AIIMS), New Delhi, India
| | - Sandeep Rai
- Department of Laboratory Oncology, Dr. B.R. Ambedkar IRCH, All India Institute of Medical Sciences (AIIMS), New Delhi, India
| | - Saroj Singh
- Department of Laboratory Oncology, Dr. B.R. Ambedkar IRCH, All India Institute of Medical Sciences (AIIMS), New Delhi, India
| | - Vijay K Prajapati
- Department of Laboratory Oncology, Dr. B.R. Ambedkar IRCH, All India Institute of Medical Sciences (AIIMS), New Delhi, India
| | - Lalit Kumar
- Department of Medical Oncology, Dr. B.R. Ambedkar IRCH, All India Institute of Medical Sciences (AIIMS), New Delhi, India
| | - Atul Sharma
- Department of Medical Oncology, Dr. B.R. Ambedkar IRCH, All India Institute of Medical Sciences (AIIMS), New Delhi, India
| | - Ranjit K Sahoo
- Department of Medical Oncology, Dr. B.R. Ambedkar IRCH, All India Institute of Medical Sciences (AIIMS), New Delhi, India
| | - Ajay Gogia
- Department of Medical Oncology, Dr. B.R. Ambedkar IRCH, All India Institute of Medical Sciences (AIIMS), New Delhi, India
| |
Collapse
|
3
|
Lebel E, Nachmias B, Pick M, Gross Even-Zohar N, Gatt ME. Understanding the Bioactivity and Prognostic Implication of Commonly Used Surface Antigens in Multiple Myeloma. J Clin Med 2022; 11:jcm11071809. [PMID: 35407416 PMCID: PMC9000075 DOI: 10.3390/jcm11071809] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2022] [Revised: 03/19/2022] [Accepted: 03/23/2022] [Indexed: 02/06/2023] Open
Abstract
Multiple myeloma (MM) progression is dependent on its interaction with the bone marrow microenvironment and the immune system and is mediated by key surface antigens. Some antigens promote adhesion to the bone marrow matrix and stromal cells, while others are involved in intercellular interactions that result in differentiation of B-cells to plasma cells (PC). These interactions are also involved in malignant transformation of the normal PC to MM PC as well as disease progression. Here, we review selected surface antigens that are commonly used in the flow cytometry analysis of MM for identification of plasma cells (PC) and the discrimination between normal and malignant PC as well as prognostication. These include the markers: CD38, CD138, CD45, CD19, CD117, CD56, CD81, CD27, and CD28. Furthermore, we will discuss the novel marker CD24 and its involvement in MM. The bioactivity of each antigen is reviewed, as well as its expression on normal vs. malignant PC, prognostic implications, and therapeutic utility. Understanding the role of these specific surface antigens, as well as complex co-expressions of combinations of antigens, may allow for a more personalized prognostic monitoring and treatment of MM patients.
Collapse
|
4
|
Rojas EA, Gutiérrez NC. Genomics of Plasma Cell Leukemia. Cancers (Basel) 2022; 14:cancers14061594. [PMID: 35326746 PMCID: PMC8946729 DOI: 10.3390/cancers14061594] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2022] [Revised: 03/12/2022] [Accepted: 03/16/2022] [Indexed: 11/30/2022] Open
Abstract
Simple Summary Plasma cell leukemia (PCL) is a very aggressive plasma cell disorder with a dismal prognosis, despite the therapeutic progress made in the last few years. The implementation of genomic high-throughput technologies in the clinical setting has revealed new insights into the genomic landscape of PCL, some of which may have an impact on the development of novel therapeutic approaches. The purpose of this review is to provide a comprehensive overview and update of the genomic studies carried out in PCL. Abstract Plasma cell leukemia (PCL) is a rare and highly aggressive plasma cell dyscrasia characterized by the presence of clonal circulating plasma cells in peripheral blood. PCL accounts for approximately 2–4% of all multiple myeloma (MM) cases. PCL can be classified in primary PCL (pPCL) when it appears de novo and in secondary PCL (sPCL) when it arises from a pre-existing relapsed/refractory MM. Despite the improvement in treatment modalities, the prognosis remains very poor. There is growing evidence that pPCL is a different clinicopathological entity as compared to MM, although the mechanisms underlying its pathogenesis are not fully elucidated. The development of new high-throughput technologies, such as microarrays and new generation sequencing (NGS), has contributed to a better understanding of the peculiar biological and clinical features of this disease. Relevant information is now available on cytogenetic alterations, genetic variants, transcriptome, methylation patterns, and non-coding RNA profiles. Additionally, attempts have been made to integrate genomic alterations with gene expression data. However, given the low frequency of PCL, most of the genetic information comes from retrospective studies with a small number of patients, sometimes leading to inconsistent results.
Collapse
Affiliation(s)
- Elizabeta A. Rojas
- Hematology Department, University Hospital of Salamanca, Institute of Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain;
- Cancer Research Center-Institute of Cancer Molecular and Cellular Biology (CIC-IBMCC) (USAL-CSIC), 37007 Salamanca, Spain
| | - Norma C. Gutiérrez
- Hematology Department, University Hospital of Salamanca, Institute of Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain;
- Cancer Research Center-Institute of Cancer Molecular and Cellular Biology (CIC-IBMCC) (USAL-CSIC), 37007 Salamanca, Spain
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), CB16/12/00233, 28029 Madrid, Spain
- Grupo Español de Mieloma (GEM), 28040 Madrid, Spain
- Correspondence: ; Tel.: +34-923-291-200 (ext. 56617)
| |
Collapse
|
5
|
Fitzpatrick MJ, Nardi V, Sohani AR. Plasma cell myeloma: role of histopathology, immunophenotyping, and genetic testing. Skeletal Radiol 2022; 51:17-30. [PMID: 33687521 DOI: 10.1007/s00256-021-03754-3] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/19/2021] [Revised: 02/27/2021] [Accepted: 03/02/2021] [Indexed: 02/02/2023]
Abstract
Myeloma is a malignant neoplasm of plasma cells with complex pathogenesis. Diagnosis and risk stratification require the integration of histology, radiology, serology, and genetic data. Bone marrow biopsies are essential for myeloma diagnosis by providing material for histologic and cytologic assessment as well as immunophenotypic and genetic studies. Flow cytometry and genetic studies are, in particular, becoming increasingly important for diagnosis, risk stratification, and assessment of treatment response. Myeloma has traditionally been characterized by recurrent cytogenetic abnormalities that can be divided into two subtypes: hyperdiploid, characterized by trisomies, and non-hyperdiploid, characterized by translocations involving chromosome 14. These abnormalities are thought to be primary events, initiating a premalignant state, which progresses to myeloma through the acquisition of secondary mutations. The emergence of next-generation sequencing has led to the discovery of numerous mutations and gene fusions that comprise the heterogenous genomic landscape of myeloma. As the underlying pathogenesis of myeloma continues to be delineated, possible therapeutic targets have also emerged. Herein, we describe the importance of histology, immunophenotype, and mutational analysis in the assessment of myeloma.
Collapse
Affiliation(s)
- Megan J Fitzpatrick
- Department of Pathology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit St, WRN 219, Boston, MA, 02114, USA
- Department of Pathology, Harvard Medical School, 25 Shattuck St, Boston, MA, 02115, USA
| | - Valentina Nardi
- Department of Pathology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit St, WRN 219, Boston, MA, 02114, USA
- Department of Pathology, Harvard Medical School, 25 Shattuck St, Boston, MA, 02115, USA
| | - Aliyah R Sohani
- Department of Pathology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit St, WRN 219, Boston, MA, 02114, USA.
- Department of Pathology, Harvard Medical School, 25 Shattuck St, Boston, MA, 02115, USA.
| |
Collapse
|
6
|
Soh KT, Tario JD, Wallace PK. Diagnosis of Plasma Cell Dyscrasias and Monitoring of Minimal Residual Disease by Multiparametric Flow Cytometry. Clin Lab Med 2018; 37:821-853. [PMID: 29128071 DOI: 10.1016/j.cll.2017.08.001] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
Plasma cell dyscrasia (PCD) is a heterogeneous disease that has seen a tremendous change in outcomes due to improved therapies. Over the past few decades, multiparametric flow cytometry has played an important role in the detection and monitoring of PCDs. Flow cytometry is a high-sensitivity assay for early detection of minimal residual disease (MRD) that correlates well with progression-free survival and overall survival. Before flow cytometry can be effectively implemented in the clinical setting, sample preparation, panel configuration, analysis, and gating strategies must be optimized to ensure accurate results. Current consensus methods and reporting guidelines for MRD testing are discussed.
Collapse
Affiliation(s)
- Kah Teong Soh
- Department of Flow and Image Cytometry, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA.
| | - Joseph D Tario
- Department of Flow and Image Cytometry, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
| | - Paul K Wallace
- Department of Flow and Image Cytometry, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
| |
Collapse
|
7
|
Ceran F, Falay M, Dağdaş S, Özet G. The Assessment of CD56 and CD117 Expressions at the Time of the Diagnosis in Multiple Myeloma Patients. Turk J Haematol 2017; 34:226-232. [PMID: 28270374 PMCID: PMC5544041 DOI: 10.4274/tjh.2016.0394] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Abstract
Objective: The purpose of this study is to investigate the relationship between the CD56 and CD117 expressions and the clinical and laboratory findings in multiple myeloma (MM) patients. Materials and Methods: Analyses of multiparametric flow cytometry data obtained from the diagnostic bone marrow aspirations of a total of 34 newly diagnosed MM patients were assessed retrospectively. CD56 and CD117 expressions of the patients were compared with their stages and clinical parameters. The staging was performed according to the International Staging System (ISS). Results: Of the patients, 58.8% had ISS stage 1-2 MM while 41.2% had stage 3 MM. The number of CD56-positive patients was 29, whereas the number of CD117-positive patients was 13. There was no statistical difference between the CD56 and CD117 expressions and extramedullary involvement and lytic bone lesions. The median beta-2 microglobulin level was higher in the CD117-negative group (p=0.047). CD56 and CD117 expression levels were found to be lower in advanced-stage patients than in early-stage ones (p=0.026 and p=0.017). The lactate dehydrogenase (LDH) levels were high in advanced-stage patients, and an inverse relationship was found between LDH level and CD117 expression. Conclusion: Our findings that the CD56 and CD117 expression levels are lower in advanced stages than earlier stages and that LDH level and CD117 expression have an inverse relationship in patients with newly diagnosed MM suggest that CD56 and CD117 expressions may be prognostic markers for MM.
Collapse
Affiliation(s)
- Funda Ceran
- Ankara Numune Training and Research Hospital, Clinic of Hematology, Ankara, Turkey
| | | | | | | |
Collapse
|
8
|
Limvorapitak W, Srisum-Ang T, Chimres C, Warnnissorn N, Kanitsap N. Accuracy of Bone Marrow Flow Cytometry Analysis in Patients With Plasma Cell Neoplasm in Thailand: A Single Institutional Study. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA 2016; 16:e27-37. [PMID: 26796980 DOI: 10.1016/j.clml.2015.12.002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/05/2015] [Revised: 11/25/2015] [Accepted: 12/08/2015] [Indexed: 11/18/2022]
Abstract
BACKGROUND Plasma cell neoplasm is a common hematologic malignancy. Treatment with novel agents results in favorable outcomes. Reliable investigations are required to monitor the residual disease, especially after such effective treatments. Flow cytometric analysis is a speedy and accurate method to detect abnormal cells. The aim of this study was to determine diagnostic performance of flow cytometry in the detection of abnormal plasma cells in bone marrow specimens. MATERIALS AND METHODS We included bone marrow samples taken from patients suspected to harbor plasma cell neoplasm at the time of diagnosis or follow-up after treatment from 2013 to 2015. Flow cytometric analyses, using cluster of differentiation (CD)19/CD20/CD27/CD38/CD45/CD56/CD117/CD138 and cytoplasmic κ/λ, were done and results compared with morphologic evaluation of marrow aspirate smear, histology, and immunohistochemistry of marrow biopsy and protein electrophoretic analyses. RESULTS A total of 154 specimens were included. Plasma cell neoplasm was detected in 56 samples (36.4%). Most abnormal plasma cells in this study were CD19-negative (CD19(-))/CD20(-)/CD27(+)/CD38(+)/CD45(-) (or weakly positive)/CD56(+)/CD117(+)/CD138(+). Light chain restriction was found only in 18 samples (32.1%). Sensitivity and specificity of flow cytometric analysis were 91.1% and 96.9%, respectively. For the follow-up cohort, sensitivity and specificity were 86.7% and 66.7%, respectively. CONCLUSION Analysis of plasma cell neoplasm using flow cytometry has high sensitivity and specificity. As an adjunct to marrow histology and immunohistochemistry, flow cytometry can be used in diagnosis of plasma cell neoplasm and more importantly in monitoring the disease after treatment. We propose a limited panel of CD19/CD38/CD45/CD56/CD117/CD138 for detecting minimal residual disease in Thai patients.
Collapse
Affiliation(s)
- Wasithep Limvorapitak
- Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Thammasat University, Pathumthani, Thailand.
| | | | - Chutima Chimres
- Pathology Unit, Thammasat University Hospital, Pathumthani, Thailand
| | - Naree Warnnissorn
- Department of Pathology and Forensic Medicine, Faculty of Medicine, Thammasat University, Pathumthani, Thailand
| | - Nonglak Kanitsap
- Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Thammasat University, Pathumthani, Thailand
| |
Collapse
|
9
|
Expression of myeloid antigen in neoplastic plasma cells is related to adverse prognosis in patients with multiple myeloma. BIOMED RESEARCH INTERNATIONAL 2014; 2014:893243. [PMID: 24991573 PMCID: PMC4065753 DOI: 10.1155/2014/893243] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/21/2014] [Revised: 04/28/2014] [Accepted: 05/08/2014] [Indexed: 01/04/2023]
Abstract
We evaluated the association between the expression of myeloid antigens on neoplastic plasma cells and patient prognosis. The expression status of CD13, CD19, CD20, CD33, CD38, CD56, and CD117 was analyzed on myeloma cells from 55 newly diagnosed patients, including 36 men (65%), of median age 61 years (range: 38–78). Analyzed clinical characteristics and laboratory parameters were as follows: serum β2-microglobulin, lactate dehydrogenase, calcium, albumin, hemoglobin, serum creatinine concentrations, bone marrow histology, and cytogenetic findings. CD13+ and CD33+ were detected in 53% and 18%, respectively. Serum calcium (P = 0.049) and LDH (P = 0.018) concentrations were significantly higher and morphologic subtype of immature or plasmablastic was more frequent in CD33+ than in CD33− patients (P = 0.022). CD33 and CD13 expression demonstrate a potential prognostic impact and were associated with lower overall survival (OS; P = 0.001 and P = 0.025) in Kaplan-Meier analysis. Multivariate analysis showed that CD33 was independently prognostic of shorter progression free survival (PFS; P = 0.037) and OS (P = 0.001) with correction of clinical prognostic factors. This study showed that CD13 and CD33 expression associated with poor prognosis in patients with MM implicating the need of analysis of these markers in MM diagnosis.
Collapse
|
10
|
Kumar S, Kimlinger T, Morice W. Immunophenotyping in multiple myeloma and related plasma cell disorders. Best Pract Res Clin Haematol 2011; 23:433-51. [PMID: 21112041 DOI: 10.1016/j.beha.2010.09.002] [Citation(s) in RCA: 87] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
Plasma cell disorders form a spectrum ranging from the asymptomatic presence of small monoclonal populations of plasma cells to conditions like plasma cell leukemia and multiple myeloma, in which the bone marrow can be replaced by the accumulation of neoplastic plasma cells. Immunophenotyping has become an invaluable tool in the management of hematological malignancies and is increasingly finding a role in the diagnosis and monitoring of plasma cell disorders. Multiparameter flow cytometry has evolved considerably during the past decade with an increasing ability to screen large numbers of events and to detect multiple antigens at the same time. This, along with a better understanding of the phenotypic heterogeneity of the clonal plasma cells in different disorders, has made immunophenotyping an indispensible tool in the diagnosis, prognostic classification and management of plasma cell disorders. This book chapter addresses the approaches taken to evaluate monoclonal plasma cell disorders, and the different markers and techniques that are important for the study of these diseases.
Collapse
Affiliation(s)
- Shaji Kumar
- Divisions of Hematology and Hematopathology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, United States.
| | | | | |
Collapse
|
11
|
Kraj M, Kopeć-Szlęzak J, Pogłód R, Kruk B. Flow cytometric immunophenotypic characteristics of 36 cases of plasma cell leukemia. Leuk Res 2011; 35:169-76. [PMID: 20553988 DOI: 10.1016/j.leukres.2010.04.021] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2010] [Revised: 04/22/2010] [Accepted: 04/23/2010] [Indexed: 12/13/2022]
Abstract
Prospective flow cytometric analysis of antigens expression on bone marrow and peripheral blood plasma cells of 36 plasma cell leukemia (PCL) patients enabled to establish the following immunophenotype of leukemic plasma cell: CD38(++), CD138(+), CD54(+), CD49d(+), CD29(+), CD44(+), CD126(+), CD19(-), CD45(-). In one-third of patients PCL cells express CD56, CD71 and CD117. Expression of CD54 on plasma cells was higher as compared to expression of adhesion molecules CD11a, CD18 and CD11b (p<0.01). Expression of CD18, CD11a, CD11b was lower on bone marrow and higher on peripheral blood cells. In conclusion, impaired expression of adhesion molecules such as CD11a/CD18 or CD56 may explain hematogenic dissemination characterizing PCL.
Collapse
Affiliation(s)
- Maria Kraj
- Department of Hematology, Institute of Hematology and Transfusion Medicine, 14 I Gandhi Street, 02-776 Warsaw, Poland.
| | | | | | | |
Collapse
|
12
|
Cannizzo E, Bellio E, Sohani AR, Hasserjian RP, Ferry JA, Dorn ME, Sadowski C, Bucci JJ, Carulli G, Preffer F. Multiparameter immunophenotyping by flow cytometry in multiple myeloma: The diagnostic utility of defining ranges of normal antigenic expression in comparison to histology. CYTOMETRY PART B-CLINICAL CYTOMETRY 2010; 78:231-8. [PMID: 20198608 DOI: 10.1002/cyto.b.20517] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
BACKGROUND Numerous studies have reported on the immunophenotype of plasma cells (PCs) in monoclonal gammopathy of undetermined significance (MGUS) and in plasma cell myeloma (PCM), but very few have examined the immunophenotype of normal PCs. In this study, an objective definition of normal range of expression for each antigen was found on normal control PCs. Using these new ranges of normal expression (new method) is different from using a static 20% of PCs cut-off for all antigens as described in the literature (traditional method). These newly calculated normal ranges for each antigen were applied to our data, and compared to histologic and immunohistochemical findings. METHODS Bone marrow samples from 46 patients with PC neoplasms and 15 normal controls were studied. A minimum of 100 PC were analyzed for each patient and control sample. An 8-color staining method was applied to study the immunophenotype of PCs, using a BD FACSCanto II. RESULTS By the new ranges of normality calculated in this study it was determined that different antigens have different level of expression on polyclonal PCs. CD19 correlated with histology by both the traditional and new methods, but had superior correlation by the new method. CONCLUSIONS This report is the first 8-color immunophenotypic study of PCM in which a "range of normal expression" for each antigen is defined. This is a critical step to help distinguish between a normal and neoplastic PC immunophenotype and discern which antigens are of diagnostic importance.
Collapse
Affiliation(s)
- Elisa Cannizzo
- Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Herbert KE, Prince HM, Ritchie DS, Seymour JF. The role of ancestim (recombinant human stem-cell factor, rhSCF) in hematopoietic stem cell mobilization and hematopoietic reconstitution. Expert Opin Biol Ther 2009; 10:113-25. [DOI: 10.1517/14712590903473123] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
14
|
Mateo G, Montalbán MA, Vidriales MB, Lahuerta JJ, Mateos MV, Gutiérrez N, Rosiñol L, Montejano L, Bladé J, Martínez R, de la Rubia J, Diaz-Mediavilla J, Sureda A, Ribera JM, Ojanguren JM, de Arriba F, Palomera L, Terol MJ, Orfao A, San Miguel JF. Prognostic Value of Immunophenotyping in Multiple Myeloma: A Study by the PETHEMA/GEM Cooperative Study Groups on Patients Uniformly Treated With High-Dose Therapy. J Clin Oncol 2008; 26:2737-44. [DOI: 10.1200/jco.2007.15.4120] [Citation(s) in RCA: 164] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Purpose To analyze the prognostic impact of immunophenotyping in patients with multiple myeloma (MM). Patients and Methods We have prospectively analyzed the prognostic impact of antigenic markers, assessed by multiparametric flow cytometry, in a series of 685 newly diagnosed MM patients that were uniformly treated according to the GEM 2000 protocol. Results Our results show that expression of both CD19 and CD28 as well as the absence of CD117 were associated with a significantly shorter progression free-survival (PFS) and overall survival (OS). Interestingly, the CD28 expression correlated with t(14;16) and del(17p), while CD117-negative patients were associated with t(4;14) and del(13q). Simultaneous assessment of CD28 and CD117 antigens allowed stratification of patients with MM into three risk categories: poor risk (CD28 positive CD117 negative), intermediate (either both markers negative or both positive), and good risk (CD28 negative CD117 positive), with PFS rates of 30, 37, and 45 months, respectively (P = .01), and OS rates of 45, 68, and not reached, respectively (P = .0001). Conclusion To the best of our knowledge, this is the first prospective analysis in which the prognostic impact of a relatively high number of antigenic markers has been simultaneously analyzed in a large series of uniformly treated patients, showing that the expression of several antigens (particularly CD28 and CD117) on bone marrow plasma cells from patients with MM can help to identify patients at high risk of progression.
Collapse
Affiliation(s)
- Gema Mateo
- From the Hospital Universitario de Salamanca; Centro de Investigación del Cáncer (CIC, IBMCC USAL-CSIC); Servicio General de Citometría, Universidad de Salamanca; Hospital 12 de Octubre; Clínico San Carlos, Madrid; Clínic Universitari Barcelona; Hospital Sant Pau Barcelona; Hospital La Fé; Clínico Universitario, Valencia; Hospital Germans Trias i Pujol Badalona; Hospital de Galdakao; Hospital Morales Messeguer, Murcia; and the Hospital Lozano Blesa, Zaragoza, Spain
| | - M. Angeles Montalbán
- From the Hospital Universitario de Salamanca; Centro de Investigación del Cáncer (CIC, IBMCC USAL-CSIC); Servicio General de Citometría, Universidad de Salamanca; Hospital 12 de Octubre; Clínico San Carlos, Madrid; Clínic Universitari Barcelona; Hospital Sant Pau Barcelona; Hospital La Fé; Clínico Universitario, Valencia; Hospital Germans Trias i Pujol Badalona; Hospital de Galdakao; Hospital Morales Messeguer, Murcia; and the Hospital Lozano Blesa, Zaragoza, Spain
| | - Maria-Belén Vidriales
- From the Hospital Universitario de Salamanca; Centro de Investigación del Cáncer (CIC, IBMCC USAL-CSIC); Servicio General de Citometría, Universidad de Salamanca; Hospital 12 de Octubre; Clínico San Carlos, Madrid; Clínic Universitari Barcelona; Hospital Sant Pau Barcelona; Hospital La Fé; Clínico Universitario, Valencia; Hospital Germans Trias i Pujol Badalona; Hospital de Galdakao; Hospital Morales Messeguer, Murcia; and the Hospital Lozano Blesa, Zaragoza, Spain
| | - Juan J. Lahuerta
- From the Hospital Universitario de Salamanca; Centro de Investigación del Cáncer (CIC, IBMCC USAL-CSIC); Servicio General de Citometría, Universidad de Salamanca; Hospital 12 de Octubre; Clínico San Carlos, Madrid; Clínic Universitari Barcelona; Hospital Sant Pau Barcelona; Hospital La Fé; Clínico Universitario, Valencia; Hospital Germans Trias i Pujol Badalona; Hospital de Galdakao; Hospital Morales Messeguer, Murcia; and the Hospital Lozano Blesa, Zaragoza, Spain
| | - Maria V. Mateos
- From the Hospital Universitario de Salamanca; Centro de Investigación del Cáncer (CIC, IBMCC USAL-CSIC); Servicio General de Citometría, Universidad de Salamanca; Hospital 12 de Octubre; Clínico San Carlos, Madrid; Clínic Universitari Barcelona; Hospital Sant Pau Barcelona; Hospital La Fé; Clínico Universitario, Valencia; Hospital Germans Trias i Pujol Badalona; Hospital de Galdakao; Hospital Morales Messeguer, Murcia; and the Hospital Lozano Blesa, Zaragoza, Spain
| | - Norma Gutiérrez
- From the Hospital Universitario de Salamanca; Centro de Investigación del Cáncer (CIC, IBMCC USAL-CSIC); Servicio General de Citometría, Universidad de Salamanca; Hospital 12 de Octubre; Clínico San Carlos, Madrid; Clínic Universitari Barcelona; Hospital Sant Pau Barcelona; Hospital La Fé; Clínico Universitario, Valencia; Hospital Germans Trias i Pujol Badalona; Hospital de Galdakao; Hospital Morales Messeguer, Murcia; and the Hospital Lozano Blesa, Zaragoza, Spain
| | - Laura Rosiñol
- From the Hospital Universitario de Salamanca; Centro de Investigación del Cáncer (CIC, IBMCC USAL-CSIC); Servicio General de Citometría, Universidad de Salamanca; Hospital 12 de Octubre; Clínico San Carlos, Madrid; Clínic Universitari Barcelona; Hospital Sant Pau Barcelona; Hospital La Fé; Clínico Universitario, Valencia; Hospital Germans Trias i Pujol Badalona; Hospital de Galdakao; Hospital Morales Messeguer, Murcia; and the Hospital Lozano Blesa, Zaragoza, Spain
| | - Laura Montejano
- From the Hospital Universitario de Salamanca; Centro de Investigación del Cáncer (CIC, IBMCC USAL-CSIC); Servicio General de Citometría, Universidad de Salamanca; Hospital 12 de Octubre; Clínico San Carlos, Madrid; Clínic Universitari Barcelona; Hospital Sant Pau Barcelona; Hospital La Fé; Clínico Universitario, Valencia; Hospital Germans Trias i Pujol Badalona; Hospital de Galdakao; Hospital Morales Messeguer, Murcia; and the Hospital Lozano Blesa, Zaragoza, Spain
| | - Joan Bladé
- From the Hospital Universitario de Salamanca; Centro de Investigación del Cáncer (CIC, IBMCC USAL-CSIC); Servicio General de Citometría, Universidad de Salamanca; Hospital 12 de Octubre; Clínico San Carlos, Madrid; Clínic Universitari Barcelona; Hospital Sant Pau Barcelona; Hospital La Fé; Clínico Universitario, Valencia; Hospital Germans Trias i Pujol Badalona; Hospital de Galdakao; Hospital Morales Messeguer, Murcia; and the Hospital Lozano Blesa, Zaragoza, Spain
| | - Rafael Martínez
- From the Hospital Universitario de Salamanca; Centro de Investigación del Cáncer (CIC, IBMCC USAL-CSIC); Servicio General de Citometría, Universidad de Salamanca; Hospital 12 de Octubre; Clínico San Carlos, Madrid; Clínic Universitari Barcelona; Hospital Sant Pau Barcelona; Hospital La Fé; Clínico Universitario, Valencia; Hospital Germans Trias i Pujol Badalona; Hospital de Galdakao; Hospital Morales Messeguer, Murcia; and the Hospital Lozano Blesa, Zaragoza, Spain
| | - Javier de la Rubia
- From the Hospital Universitario de Salamanca; Centro de Investigación del Cáncer (CIC, IBMCC USAL-CSIC); Servicio General de Citometría, Universidad de Salamanca; Hospital 12 de Octubre; Clínico San Carlos, Madrid; Clínic Universitari Barcelona; Hospital Sant Pau Barcelona; Hospital La Fé; Clínico Universitario, Valencia; Hospital Germans Trias i Pujol Badalona; Hospital de Galdakao; Hospital Morales Messeguer, Murcia; and the Hospital Lozano Blesa, Zaragoza, Spain
| | - Joaquín Diaz-Mediavilla
- From the Hospital Universitario de Salamanca; Centro de Investigación del Cáncer (CIC, IBMCC USAL-CSIC); Servicio General de Citometría, Universidad de Salamanca; Hospital 12 de Octubre; Clínico San Carlos, Madrid; Clínic Universitari Barcelona; Hospital Sant Pau Barcelona; Hospital La Fé; Clínico Universitario, Valencia; Hospital Germans Trias i Pujol Badalona; Hospital de Galdakao; Hospital Morales Messeguer, Murcia; and the Hospital Lozano Blesa, Zaragoza, Spain
| | - Anna Sureda
- From the Hospital Universitario de Salamanca; Centro de Investigación del Cáncer (CIC, IBMCC USAL-CSIC); Servicio General de Citometría, Universidad de Salamanca; Hospital 12 de Octubre; Clínico San Carlos, Madrid; Clínic Universitari Barcelona; Hospital Sant Pau Barcelona; Hospital La Fé; Clínico Universitario, Valencia; Hospital Germans Trias i Pujol Badalona; Hospital de Galdakao; Hospital Morales Messeguer, Murcia; and the Hospital Lozano Blesa, Zaragoza, Spain
| | - José M. Ribera
- From the Hospital Universitario de Salamanca; Centro de Investigación del Cáncer (CIC, IBMCC USAL-CSIC); Servicio General de Citometría, Universidad de Salamanca; Hospital 12 de Octubre; Clínico San Carlos, Madrid; Clínic Universitari Barcelona; Hospital Sant Pau Barcelona; Hospital La Fé; Clínico Universitario, Valencia; Hospital Germans Trias i Pujol Badalona; Hospital de Galdakao; Hospital Morales Messeguer, Murcia; and the Hospital Lozano Blesa, Zaragoza, Spain
| | - José M. Ojanguren
- From the Hospital Universitario de Salamanca; Centro de Investigación del Cáncer (CIC, IBMCC USAL-CSIC); Servicio General de Citometría, Universidad de Salamanca; Hospital 12 de Octubre; Clínico San Carlos, Madrid; Clínic Universitari Barcelona; Hospital Sant Pau Barcelona; Hospital La Fé; Clínico Universitario, Valencia; Hospital Germans Trias i Pujol Badalona; Hospital de Galdakao; Hospital Morales Messeguer, Murcia; and the Hospital Lozano Blesa, Zaragoza, Spain
| | - Felipe de Arriba
- From the Hospital Universitario de Salamanca; Centro de Investigación del Cáncer (CIC, IBMCC USAL-CSIC); Servicio General de Citometría, Universidad de Salamanca; Hospital 12 de Octubre; Clínico San Carlos, Madrid; Clínic Universitari Barcelona; Hospital Sant Pau Barcelona; Hospital La Fé; Clínico Universitario, Valencia; Hospital Germans Trias i Pujol Badalona; Hospital de Galdakao; Hospital Morales Messeguer, Murcia; and the Hospital Lozano Blesa, Zaragoza, Spain
| | - Luis Palomera
- From the Hospital Universitario de Salamanca; Centro de Investigación del Cáncer (CIC, IBMCC USAL-CSIC); Servicio General de Citometría, Universidad de Salamanca; Hospital 12 de Octubre; Clínico San Carlos, Madrid; Clínic Universitari Barcelona; Hospital Sant Pau Barcelona; Hospital La Fé; Clínico Universitario, Valencia; Hospital Germans Trias i Pujol Badalona; Hospital de Galdakao; Hospital Morales Messeguer, Murcia; and the Hospital Lozano Blesa, Zaragoza, Spain
| | - Maria J. Terol
- From the Hospital Universitario de Salamanca; Centro de Investigación del Cáncer (CIC, IBMCC USAL-CSIC); Servicio General de Citometría, Universidad de Salamanca; Hospital 12 de Octubre; Clínico San Carlos, Madrid; Clínic Universitari Barcelona; Hospital Sant Pau Barcelona; Hospital La Fé; Clínico Universitario, Valencia; Hospital Germans Trias i Pujol Badalona; Hospital de Galdakao; Hospital Morales Messeguer, Murcia; and the Hospital Lozano Blesa, Zaragoza, Spain
| | - Alberto Orfao
- From the Hospital Universitario de Salamanca; Centro de Investigación del Cáncer (CIC, IBMCC USAL-CSIC); Servicio General de Citometría, Universidad de Salamanca; Hospital 12 de Octubre; Clínico San Carlos, Madrid; Clínic Universitari Barcelona; Hospital Sant Pau Barcelona; Hospital La Fé; Clínico Universitario, Valencia; Hospital Germans Trias i Pujol Badalona; Hospital de Galdakao; Hospital Morales Messeguer, Murcia; and the Hospital Lozano Blesa, Zaragoza, Spain
| | - Jesús F. San Miguel
- From the Hospital Universitario de Salamanca; Centro de Investigación del Cáncer (CIC, IBMCC USAL-CSIC); Servicio General de Citometría, Universidad de Salamanca; Hospital 12 de Octubre; Clínico San Carlos, Madrid; Clínic Universitari Barcelona; Hospital Sant Pau Barcelona; Hospital La Fé; Clínico Universitario, Valencia; Hospital Germans Trias i Pujol Badalona; Hospital de Galdakao; Hospital Morales Messeguer, Murcia; and the Hospital Lozano Blesa, Zaragoza, Spain
| |
Collapse
|
15
|
Abstract
Flow cytometric immunophenotyping remains an indispensable tool for the diagnosis, classification, staging, and monitoring of hematologic neoplasms. The last 10 years have seen advances in flow cytometry instrumentation and availability of an expanded range of antibodies and fluorochromes that have improved our ability to identify different normal cell populations and recognize phenotypic aberrancies, even when present in a small proportion of the cells analyzed. Phenotypically abnormal populations have been documented in many hematologic neoplasms, including lymphoma, chronic lymphoid leukemias, plasma cell neoplasms, acute leukemia, paroxysmal nocturnal hemoglobinuria, mast cell disease, myelodysplastic syndromes, and myeloproliferative disorders. The past decade has also seen refinement of the criteria used to identify distinct disease entities with widespread adoption of the 2001 World Health Organization (WHO) classification. This classification endorses a multiparametric approach to diagnosis and outlines the morphologic, immunophenotypic, and genotypic features characteristic of each disease entity. When should flow cytometric immunophenotyping be applied? The recent Bethesda International Consensus Conference on flow cytometric immunophenotypic analysis of hematolymphoid neoplasms made recommendations on the medical indications for flow cytometric testing. This review discusses how flow cytometric testing is currently applied in these clinical situations and how the information obtained can be used to direct other testing.
Collapse
|
16
|
Rezaï K, Lokiec F, Grandjean I, Weill S, de Cremoux P, Bordier V, Ekue R, Garcia M, Poupon MF, Decaudin D. Impact of imatinib on the pharmacokinetics and in vivo efficacy of etoposide and/or ifosfamide. BMC Pharmacol 2007; 7:13. [PMID: 17963518 PMCID: PMC2180168 DOI: 10.1186/1471-2210-7-13] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2007] [Accepted: 10/27/2007] [Indexed: 12/28/2022] Open
Abstract
Background Using a human small cell lung cancer (SCLC) xenografted in nude mice, we have previously reported enhanced tumor growth inhibition following chemotherapy in combination with imatinib (STI571). We therefore investigated the in vivo impact of imatinib on the pharmacokinetics and efficacy of chemotherapy. Methods Two different human tumors were used: SCLC6 small cell lung cancer xenografted in nude mice, and LY-3 EBV-associated human B-cell lymphoma xenografted in SCID mice. Plasma, urine, and fecal concentrations of etoposide (VP16) were determined by a validated high performance liquid chromatography method. Plasma concentrations of ifosfamidewere determined by a validated gas chromatography assay with nitrogen-phosphorus detection. Results Slight tumor growth inhibition was induced by imatinib administered alone in one in vivo EBV-associated B-cell lymphomatous xenograft. In contrast, an increase of the chemotherapy-induced antitumor effect was observed in the lymphoma model but not in a small cell lung cancer model when mice bearing human xenografted tumors were treated concomitantly by imatinib and chemotherapy. This antitumor effect was not influenced by concomitant administration of fluconazole. The AUC0-3 h (Area Under the concentration-time Curve) of etoposide was increased when mice were treated with etoposide + imatinib due to decreased fecal excretion. In contrast, imatinib did not appear to influence the urinary excretion of etoposide, and concomitant administration of the CYP3A4 inhibitor, fluconazole, with imatinib did not modify the pharmacokinetics of etoposide plus imatinib alone. Conclusion Altogether, these results therefore justify further prospective phase I and II clinical trials with combinations of etoposide-based chemotherapy and imatinib in patients with certain cancers, such as malignant lymphoma, with careful toxicologic monitoring.
Collapse
Affiliation(s)
- Keyvan Rezaï
- Department of Clinical Hematology, Institut Curie, Paris, France.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Bataille R, Pellat-Deceunynck C, Robillard N, Avet-Loiseau H, Harousseau JL, Moreau P. CD117 (c-kit) is aberrantly expressed in a subset of MGUS and multiple myeloma with unexpectedly good prognosis. Leuk Res 2007; 32:379-82. [PMID: 17767956 DOI: 10.1016/j.leukres.2007.07.016] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2007] [Revised: 07/17/2007] [Accepted: 07/23/2007] [Indexed: 10/22/2022]
Abstract
CD117 (c-kit) was evaluated on normal plasma cells (PC) (n=10), PC of individuals with monoclonal gammopathy of undetermined significance (MGUS, n=12), malignant PC from patients with multiple myeloma (MM) either at diagnosis (n=83) or relapse (n=38) and on 23 human myeloma cell lines (HMCL). Whereas CD117 is never expressed in normal PC, it is expressed in 50% of MGUS (p=0.015). Furthermore, 33% of MM at diagnosis do express CD117, as opposed to 8% of those in relapse (p=0.003). Finally, CD117 was never found in HMCL. CD117 expression was associated with a better prognosis: overall survival was 93% at 4 years in CD117+ MM versus 64% in CD117- MM (p=0.05). Conversely, lack of CD117, but also high beta-2 microglobulin, t(4;14) and CD221 (IGF-1R) expression were associated with a poorer prognosis. Multivariate analysis revealed that CD117- patients were those with CD221 and t(4;14) and had the poorest prognosis. In conclusion, CD117 (c-kit) is aberrantly expressed on a subset of MGUS and MM with a more indolent presentation and is functionally antinomic to CD221 (IGF-1R). CD117 expression could be related to a specific oncogenic pathway in MM.
Collapse
|
18
|
Vakiani E, Cattoretti G, Colovai AI, Murty VV, Alobeid B, Bhagat G. CD117 expression in diffuse large B-cell lymphomas: fact or fiction? Pathol Int 2005; 55:716-23. [PMID: 16271084 DOI: 10.1111/j.1440-1827.2005.01893.x] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
CD117 (KIT) is expressed in a variety of hematopoietic neoplasms but there are a paucity of data regarding its expression in diffuse large B-cell lymphomas (DLBCL). The purpose of the present paper was to describe the authors' experience of two CD117+ DLBCL (one of follicle center-cell origin and one nasal Epstein-Barr virus (EBV)- plasmablastic lymphoma associated with lytic bone lesions), as determined by tissue immunohistochemistry and flow cytometry. The CD117 expression in DLBCL was further evaluated using tissue microarrays and seven additional plasmablastic lymphomas, using two commercially available anti-CD117 antibodies (Ab-1, Oncogene and A4502, DakoCytomation). Membranous +/- cytoplasmic staining was seen with Ab-1 in 24/65 (37%) DLBCL, including 21/56 microarray DLBCL, two index cases, and 1/7 additional plasmablastic lymphomas, with persistent staining in 13% of microarray DLBCL despite preincubation with KIT peptide. However, A4502 had only membranous staining of the index cases and one additional EBV- plasmablastic lymphoma with medullary disease. The present study suggests that (i) CD117 expression can be detected sporadically in DLBCL of follicle center-cell origin and a subset of plasmablastic lymphomas; (ii) staining for CD117 might help in identifying EBV- plasmablastic lymphomas associated with bone marrow involvement; and (iii) CD117 antibodies should be carefully validated prior to use, because non-specific staining, as observed with Ab-1, could lead to false-positive results.
Collapse
MESH Headings
- Bone Neoplasms/chemistry
- Bone Neoplasms/immunology
- Bone Neoplasms/pathology
- Female
- Hodgkin Disease/immunology
- Hodgkin Disease/metabolism
- Hodgkin Disease/pathology
- Humans
- Immunohistochemistry
- Leukemia, Lymphocytic, Chronic, B-Cell/chemistry
- Leukemia, Lymphocytic, Chronic, B-Cell/immunology
- Leukemia, Lymphocytic, Chronic, B-Cell/pathology
- Lymphoma, B-Cell/chemistry
- Lymphoma, B-Cell/immunology
- Lymphoma, B-Cell/pathology
- Lymphoma, Follicular/chemistry
- Lymphoma, Follicular/immunology
- Lymphoma, Follicular/pathology
- Lymphoma, Large B-Cell, Diffuse/chemistry
- Lymphoma, Large B-Cell, Diffuse/immunology
- Lymphoma, Large B-Cell, Diffuse/pathology
- Lymphoma, Mantle-Cell/chemistry
- Lymphoma, Mantle-Cell/immunology
- Lymphoma, Mantle-Cell/pathology
- Male
- Middle Aged
- Mouth Neoplasms/chemistry
- Mouth Neoplasms/immunology
- Mouth Neoplasms/pathology
- Proto-Oncogene Proteins c-kit/analysis
- Proto-Oncogene Proteins c-kit/immunology
- Skin Neoplasms/chemistry
- Skin Neoplasms/immunology
- Skin Neoplasms/pathology
- Soft Tissue Neoplasms/chemistry
- Soft Tissue Neoplasms/immunology
- Soft Tissue Neoplasms/pathology
- Splenic Neoplasms/chemistry
- Splenic Neoplasms/immunology
- Splenic Neoplasms/pathology
- Stomach Neoplasms/chemistry
- Stomach Neoplasms/immunology
- Stomach Neoplasms/pathology
Collapse
Affiliation(s)
- Efsevia Vakiani
- Department of Pathology, Columbia University, New York, NY, USA
| | | | | | | | | | | |
Collapse
|